FineImmune Biotech Celebrates Grand Opening and Strategic Cell Storage Partnership in Zhongshan

On April 15, in Zhongshan Torch High-tech Zone, a grand event focusing on the cell therapy field —— FanEn(Zhongshan)Biopharmaceutical Co., Ltd.(hereinafter referred to as "Pan-Eng Bio")Grand Opening of the Strategic Signing Ceremony for Business Launch and Cell Storage. Themed "Pan-En Innovation, Intelligent Life Protection," the event attracted government representatives, industry experts, investment institutions, and partners to witness Pan-En Bio's significant strategic layout in the cell therapy field, marking a new journey for industrial development.

At the opening of the ceremony, Professor Penghui Zhou, founder and chief scientist of FanEn Biotech, emotionally reviewed the company's journey of overcoming challenges in scientific research. He emphasized the company's core mission of "guarding life and health with cell technology" and shared the strategic plans for the future: The company will continue to invest in the research, development, and transformation of highly effective immunotherapy technologies and products for solid tumors, while actively engaging in in-depth joint research and development with medical institutions and scientific research institutes, fully promoting innovation and breakthroughs in the cell therapy industry.

Speech by the company founder, Professor Penghui Zhou

During the congratulatory session, Dr. Wangqian Luo, shareholder representative of the company and co-founding partner of Huafang Capital, delivered a speech to extend warm congratulations on the company’s opening and production launch. He pointed out that the shareholders are optimistic about the prospects of the cell therapy industry and the company's potential, and will continue to provide comprehensive support in terms of funding and resource integration. They also expect the company to focus on the field of cell therapy, continuously innovate, address the challenges of solid tumor immunotherapy, achieve the transformation of scientific research results, enhance competitiveness, become an industry leader, drive industrial development, and benefit patients.

Dr. Wangqian Luo, Representative of the Company's Shareholders, Delivers a Speech

Wu Yanguang, Secretary of the Party Committee of the Zhongshan Health Base Park, attended in person and delivered an important speech. He emphasized the critical position of cell therapy within the strategic emerging industry landscape and highly recognized the significant potential of FanEn Bio in technology research and development and industrialization growth. At the same time, he solemnly pledged that the Health Base would continue to optimize the business environment, providing solid support for the clustered development of biopharmaceutical enterprises, and assisting companies like FanEn Bio to thrive.

Wu Yanguang, Deputy Secretary of the Party Committee of Zhongshan City Health Base Park, delivered a speech.

Under the watchful eyes of all guests present, the company leaders and guest representatives walked onto the stage together, holding golden scissors. As the golden scissors cut through the ribbon and fireworks burst into the air, the atmosphere reached its peak. This significant moment marked the official launch of FanEn Bio into operation, signifying its firm first step in the cell therapy industry and the beginning of a brand-new journey of development.

Ribbon-cutting Ceremony

After the ribbon-cutting ceremony, the highly anticipated strategic cooperation signing for cell storage was officially held. FanEn Bio and Beihao Stem Cell & Regenerative Medicine Research Institute, as well as Guangdong Kangze Cell Technology Co., Ltd., reached an in-depth cooperation and jointly signed the tripartite cell storage strategic cooperation agreement. This collaboration will integrate the superior resources of all parties, accelerate technological innovation in the core business of cell storage, jointly advance novel cell therapies to the international forefront, and inject strong momentum into industry development.

Signing Ceremony

After the ceremony, the guests moved to the workshop to participate in the unveiling ceremony of FanEn Bio. Professor Zhou Penghui, the founder of the company, and Secretary Hu Nan, the Party Working Committee Deputy Secretary of Zhongshan Port Street, unveiled the company's plaque together, marking the official debut of FanEn Bio.

Subsequently, under the enthusiastic leadership of the company's executives, the guests visited the GMP workshop in an orderly manner. The advanced research system, high-end experimental equipment, and rigorous scientific research atmosphere left a deep impression on the guests. Everyone highly praised Pan-Eng Bio's technical strength and industrialization prospects, and expressed great anticipation for the company’s future development.

Hu Nan, Deputy Secretary of the Zhongshan Port Subdistrict Working Committee, Participates in the Company's Unveiling Ceremony

Visit GMP Workshop

This opening event fully showcased Pan-Earth Bio's strategic ambition and innovative strength in the field of cell therapy. Through diversified approaches such as government-enterprise collaboration and cross-industry cooperation, new vitality and momentum have been injected into the cell therapy industry. Against the backdrop of continuously strengthening policy support and accelerating technological iteration, China's cell therapy industry is steadily moving towards a new stage of standardized and international development. Pan-Earth Bio will also stand at the forefront of this wave, contributing more to the protection of life and health.

Pan-E Bio is an innovative biopharmaceutical company co-founded by several returned doctors, including Harvard University returnee scholars and recipients of the "National Key Talent Project," mainly engaged in the development of immunotherapy drugs for solid tumors and related businesses.

The company's individualized TCR-T cell therapy, TAL-T cell therapy, and other new cell therapy drugs are currently undergoing Phase I clinical trials and IIT clinical studies at the Cancer Hospital of Sun Yat-sen University, Hainan Tumor Hospital, and the Second Affiliated Hospital of Hainan Medical University.

Exciting Live Broadcast Preview

Press and hold to scan the QR code and participate immediately ↓

Swipe up to view

Recommendation 1

April 17 (Thursday) 19:00 - 20:30

From Plasmids to Transfection: Breakthroughs in Key Raw Material Technologies and Practical Compliance Experience in AAV Scale Production

Recommendation 2

April 18th (Friday) 15:00-16:00

Exploration of Upstream Cultivation Processes in CGT: How to Address Long Development Cycles/Low Yields/High Costs?

Recommendation 3

April 23rd, 19:00-20:00

Technical Strategies and Research Progress of In Vivo CAR-T —— Latest Research Data and Feasibility Assessment of In Vivo CAR-T

Recommendation 4

April 28th, 19:00-20:00

Industry-Academia Dialogue: Innovation and Translation of CAR-NK Therapy for Solid Tumors

In Partnership with 医麦客 IBI EXPO 2026

Dian Dian "Share”、“Like"And"In View", charge me up a bit~"